Last updated: February 20, 2026
What Is the Product and Its Therapeutic Category?
NDC 00955-1054 refers to Eptacog Alfa (Recombinant), also known as Novoeight or NovoSeven RT, a recombinant activated factor VII used for bleeding episodes in hemophilia patients with inhibitors.
Market Size and Demand Drivers
Global Hemophilia Market: Estimated at $11.4 billion in 2022, expected to grow at a CAGR of 7.5% through 2030 (Grand View Research).
Target Population:
- Hemophilia A and B with inhibitors account for approximately 4,500 U.S. patients.
- An estimated 30% of hemophilia A patients develop inhibitors, equating to roughly 1,350 U.S. patients.
- Global prevalence of hemophilia with inhibitors is approximately 25,000 patients.
Reimbursement and Access:
- Treatment costs per infusion range from $15,000 to $50,000.
- The high cost influences prescribing patterns and insurance coverage.
Competitive Landscape
Main competitors include:
- Boehringer Ingelheim’s RiVaroxaban: Under development.
- Baxalta (a Takeda company)’s Feiba: Focused on bypassing agents.
- Novo Nordisk’s NovoSeven: Market leader with over 97% market share among licensed bypassing agents in the US.
Market Share Breakdown:
| Company |
Market Share (US, 2022) |
Product |
Annual Revenue (Estimated) |
| Novo Nordisk |
97% |
NovoSeven RT |
$1.2 billion |
| Others |
3% |
Various |
<$50 million |
Regulatory Environment
- Approved in the US (FDA) in 2010.
- Approved in the EU in 2011.
- Considered standard of care for hemophilia patients with inhibitors.
Price Trends and Projections
Current Pricing
- Per dose: Range from $25,000 to $50,000 depending on dosage and patient weight.
- Annual treatment costs: Typically $300,000 to $1 million per patient.
Price Drivers
- Patent protection expiration: Patent originally granted in 2006; primary patent expiring around 2024.
- Competition introduction: Small molecule therapies and biosimilars may emerge, exerting downward pressure.
- Manufacturing costs and R&D investment influence pricing.
Expected Price Trajectory (2023–2027)
| Year |
Price Range (per dose) |
Key Factors |
| 2023 |
$25,000 – $50,000 |
Patent expiry looming, potential biosimilar entries |
| 2024 |
$23,000 – $48,000 |
Biosimilar market entry, price discounts begin |
| 2025 |
$20,000 – $45,000 |
Market stabilization, biosimilar competition intensifies |
| 2026 |
$18,000 – $42,000 |
Continued pressure, negotiated discounts increase |
| 2027 |
$15,000 – $40,000 |
Adoption of biosimilar therapies, price normalization |
Impact of Biosimilars
Biosimilar development authorized by FDA expected post-2024. Forecasts suggest a 20–30% reduction in prices once biosimilars launch.
Investment and Commercial Strategies
- Manufacturers should focus on patent extensions, data exclusivity, and pipeline innovation.
- Pricing strategies will need to adjust to biosimilar competition and evolving treatment paradigms.
- Reimbursement negotiations will become increasingly critical to maintain margins.
Key Takeaways
- The market is dominated by Novo Nordisk’s NovoSeven RT, with high treatment costs.
- Patent expiry around 2024 prompts potential price declines and biosimilar entry.
- Prices per dose are projected to decline by approximately 20–40% over five years.
- The overall market growth is driven by increasing prevalence and acceptance of bypassing agents.
- Entry of biosimilars will likely be the primary factor influencing pricing strategies.
FAQs
-
When does the patent for NDC 00955-1054 expire?
The primary patent expiring around 2024.
-
How will biosimilar entry affect prices?
Biosimilars are expected to reduce prices by 20–30%, leading to significant cost savings in treatment.
-
What is the annual market size for this drug?
Estimated at over $1.2 billion in the US, with global sales exceeding $1.5 billion.
-
Are there regulatory hurdles for biosimilar approval?
Yes, biosimilars must demonstrate bioequivalence and safety per FDA guidelines, which can delay market entry.
-
What are alternative therapies emerging in this space?
Gene therapies for hemophilia B are under development; however, they remain in early clinical stages and are not yet commercially available.
References
[1] Grand View Research. (2022). Hemophilia Market Size, Share & Trends Analysis Report.
[2] FDA. (2022). Biosimilar Approval Pathway.
[3] EvaluatePharma. (2022). Hemophilia Drugs Market Data.
[4] IQVIA. (2022). Biologic and Biosimilar Market Trends.
